Holen Sie sich die Stockscreener-App
9.87
4.36%
-0.45
Vorhandelsmarkt:
9.99
0.12
+1.22%
Schlusskurs vom Vortag:
$10.32
Offen:
$10.28
24-Stunden-Volumen:
961.23K
Relative Volume:
1.48
Marktkapitalisierung:
$531.30M
Einnahmen:
$217.25M
Nettoeinkommen (Verlust:
$-50.92M
KGV:
-9.87
EPS:
-1
Netto-Cashflow:
$-100.85M
1W Leistung:
-11.64%
1M Leistung:
-6.27%
6M Leistung:
+87.64%
1J Leistung:
-32.16%
1-Tages-Spanne:
$9.69
$10.32
1-Wochen-Bereich:
$9.69
$11.57
52-Wochen-Spanne:
$4.32
$17.66
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Vergleichen Sie PRTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
9.87 | 555.53M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Ready to Jump After Recent Trade: Prothena Corporation plc (PRTA) - Setenews
Prothena (PRTA) price target increased by 10.91% to 20.74 - MSN
How the Narrative Surrounding Prothena Is Changing After New Pipeline and Valuation Updates - Yahoo Finance
Prothena (PRTA) Price Target Increased by 10.91% to 20.74 - Nasdaq
Will Prothena Corporation plc stock outperform international peersTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Prothena (NASDAQ:PRTA) Stock Price Up 7.4%Here's Why - MarketBeat
Are Smart Investors Making the Right Decision? Prothena Corporation plc (PRTA) - Setenews
Prothena Corp (PRTA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Citizens Jmp Forecasts Strong Price Appreciation for Prothena (NASDAQ:PRTA) Stock - MarketBeat
Prothena (NASDAQ:PRTA) Price Target Raised to $19.00 at Citizens Jmp - Defense World
Prothena stock price target raised to $19 from $11 at Citizens - Investing.com Nigeria
Prothena stock price target raised to $19 from $11 at Citizens By Investing.com - Investing.com South Africa
Citizens Raises Price Target for Prothena Corp (PRTA) to $19.00 - GuruFocus
Prothena Corporation plc Stock Analysis and ForecastFundamental Stock Analysis & Double Digit Portfolio Growth - earlytimes.in
Why (PRTA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Aug PreEarnings: Why Prothena Corporation plc stock remains undervaluedRecession Risk & Target Return Focused Stock Picks - BỘ NỘI VỤ
DCF Advisers LLC Lowers Stock Position in Prothena Corporation plc $PRTA - MarketBeat
What analysts say about Prothena Corporation plc stockInterest Rate Changes & Small Budget Capital Gains - earlytimes.in
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Prothena (NASDAQ:PRTA) Raised to "Strong-Buy" at Chardan Capital - MarketBeat
Prothena (NASDAQ:PRTA) Upgraded at Chardan Capital - Defense World
How Prothena Corporation plc stock performs during Fed tightening cyclesJuly 2025 Reactions & Low Risk Entry Point Guides - newser.com
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - BioSpace
Will Prothena Corporation plc stock see PE expansionQuarterly Growth Report & Free Reliable Trade Execution Plans - newser.com
Prothena Shareholders Approve Capital Reduction Proposal - TipRanks
Prothena presents TDP-43 CYTOPE data showing promise for ALS treatment - Investing.com Australia
Prothena (PRTA) Highlights Breakthrough in Drug Delivery at Neur - GuruFocus
Prothena announces poster presentation on its TDP-43 Cytope® program at neuroscience 2025 - MarketScreener
Prothena Announces Poster Presentation On Its TDP-43 Cytope® Program At Neuroscience 2025 - TradingView
What’s the recovery path for long term holders of Prothena Corporation plcPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Will Prothena Corporation plc stock see insider buyingWeekly Trend Summary & Community Shared Stock Ideas - newser.com
Understanding Momentum Shifts in (PRTA) - news.stocktradersdaily.com
Will Prothena Corporation plc stock maintain momentum in 2025 - newser.com
Market reaction to Prothena Corporation plc’s recent newsWeekly Market Summary & Fast Entry High Yield Tips - newser.com
What MACD and RSI say about Prothena Corporation plcTrade Performance Summary & Community Verified Watchlist Alerts - newser.com
Can Prism Finance Limited Outperform Index Funds Over the Next 5 YearsEnergy Sector Updates & Outstanding Investment Returns - earlytimes.in
What drives Prothena Corporation plc stock pricePrice Action Analysis & Low Risk Investment Plans - earlytimes.in
Can Asarfi Hospital Limited Reach New Highs in YEAR Resistance Levels ReviewedInsider Trading Activity & Test Our Stock Screener — Free Forever - earlytimes.in
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):